RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:MBC phase 3Should read: This view appears to place pelareorep in a favorable position for an early Accelerated Approval in mBC .... and reinforces the need for ONCY to pursue the FDAs actions in relaxing regulations involving early drug approval in diseases with unmet medical treatment needs, such as Her2- mBC, where ADCs are not indicated.